AG2R LA Mondiale Gestion D Actifs Makes New $1.47 Million Investment in IDEXX Laboratories, Inc. $IDXX

Key Points

• AG2R LA Mondiale Gestion D Actifs invested approximately $1.47 million in IDEXX Laboratories by purchasing 3,501 shares in the first quarter of the year.
• Wall Street analysts have raised their ratings on IDEXX Laboratories, with a consensus price target of $649.44, indicating a favorable outlook for the company's stock.
• IDEXX Laboratories reported a 10.6% year-over-year revenue increase to $1.11 billion for the quarter, exceeding analysts' expectations.

AG2R LA Mondiale Gestion D Actifs bought a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 3,501 shares of the company's stock, valued at approximately $1,470,000.

Other institutional investors also recently made changes to their positions in the company. MorganRosel Wealth Management LLC purchased a new stake in shares of IDEXX Laboratories during the 1st quarter valued at $26,000. Migdal Insurance & Financial Holdings Ltd. grew its stake in shares of IDEXX Laboratories by 55.6% during the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company's stock valued at $35,000 after buying an additional 30 shares during the period. WPG Advisers LLC purchased a new stake in shares of IDEXX Laboratories during the 1st quarter valued at $37,000. Bank of Jackson Hole Trust grew its stake in shares of IDEXX Laboratories by 328.6% during the 1st quarter. Bank of Jackson Hole Trust now owns 90 shares of the company's stock valued at $39,000 after buying an additional 69 shares during the period. Finally, Cornerstone Planning Group LLC grew its stake in shares of IDEXX Laboratories by 108.0% during the 1st quarter. Cornerstone Planning Group LLC now owns 104 shares of the company's stock valued at $44,000 after buying an additional 54 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on IDXX shares. Wall Street Zen raised shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Saturday, July 12th. Stifel Nicolaus set a $640.00 price objective on shares of IDEXX Laboratories in a research note on Monday, August 4th. JPMorgan Chase & Co. lifted their target price on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the company an "overweight" rating in a report on Monday, August 4th. Leerink Partners lifted their target price on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a report on Thursday, July 17th. Finally, Jefferies Financial Group started coverage on shares of IDEXX Laboratories in a report on Tuesday, July 1st. They set a "buy" rating and a $625.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $649.44.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $641.14 on Friday. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $688.12. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $51.29 billion, a price-to-earnings ratio of 53.38, a PEG ratio of 4.18 and a beta of 1.56. The firm's fifty day simple moving average is $603.59 and its 200 day simple moving average is $513.68.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported $3.63 EPS for the quarter, topping analysts' consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the previous year, the business posted $2.44 EPS. The firm's revenue was up 10.6% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 2,187 shares of the business's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total value of $1,415,710.71. Following the transaction, the director owned 262 shares in the company, valued at $169,600.46. The trade was a 89.30% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Jonathan Jay Mazelsky sold 29,260 shares of the business's stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $631.98, for a total transaction of $18,491,734.80. Following the completion of the transaction, the chief executive officer owned 83,311 shares in the company, valued at $52,650,885.78. This represents a 25.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 54,057 shares of company stock worth $34,293,468 over the last three months. Insiders own 0.98% of the company's stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.